Stockscreener 앱 받기
3.16
4.82%
-0.16
시간 외 거래:
3.20
0.04
+1.27%
전일 마감가:
$3.32
열려 있는:
$3.37
하루 거래량:
878.73K
Relative Volume:
0.57
시가총액:
$224.90M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-1.1835
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
+18.80%
1개월 성능:
+14.49%
6개월 성능:
+47.66%
1년 성능:
-51.90%
1일 변동 폭
$3.13
$3.375
1주일 범위
$2.78
$3.65
52주 변동 폭
$1.085
$7.14
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
3.16 | 236.29M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
C4 Therapeutics’ myeloma drug shows 50% response rate in trial - Investing.com
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting - The Manila Times
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple - GlobeNewswire
50% Response Rate: C4T's New Multiple Myeloma Drug Shows Promise with 9.3-Month Duration - Stock Titan
Dividend Watch: Whats the MACD signal for C4 Therapeutics Inc2025 Big Picture & Long Hold Capital Preservation Plans - khodrobank.com
Barclays Begins Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Performance Recap: Can C4 Therapeutics Inc reach resistance levels soonMarket Volume Report & Safe Entry Trade Reports - khodrobank.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
202,000 Shares at $1.20: Tenaya Therapeutics Grants Inducement Stock Options to New Employees - Stock Titan
C4 Therapeutics (NASDAQ:CCCC) Coverage Initiated at Barclays - MarketBeat
C4 Therapeutics (CCCC): Evaluating Valuation After Analyst Upgrade and Pipeline Developments - Yahoo Finance
697,653 Shares in C4 Therapeutics, Inc. $CCCC Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
C4 Therapeutics (NASDAQ:CCCC) Stock Rating Upgraded by Stephens - MarketBeat
Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) wi - GuruFocus
Barclays Initiates Coverage of C4 Therapeutics (CCCC) with Overweight Recommendation - Nasdaq
Portfolio Update: Will C4 Therapeutics Inc. benefit from current market trends2025 Retail Activity & Smart Allocation Stock Tips - خودرو بانک
Momentum Shift: Will C4 Therapeutics Inc stock benefit from M APortfolio Update Summary & Technical Buy Zone Confirmation - khodrobank.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully - 富途牛牛
Does FDA Progress Reinforce C4 Therapeutics' (CCCC) Platform Validation Story in Autoimmune Disease? - Yahoo Finance
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Surprises Report: Will C4 Therapeutics Inc outperform during market ralliesEarnings Overview Report & Long-Term Investment Growth Plans - khodrobank.com
Why C4 Therapeutics Stock Crushed the Market on Monday - Yahoo Finance
Risk Hedge: Should I set a stop loss on Reservoir Media Inc. Equity WarrantWeekly Trend Recap & Detailed Earnings Play Strategies - خودرو بانک
Aug Reactions: Is C4 Therapeutics Inc a good ESG investmentJuly 2025 Snapshot & Safe Swing Trade Setups - khodrobank.com
Valuation Update: Does RSVR have consistent dividend growthWeekly Profit Recap & Risk Managed Investment Strategies - خودرو بانک
C4 Therapeutics (CCCC) Rating Upgraded by Stephens & Co. with Price Target Increase | CCCC Stock News - GuruFocus
Inflation Data: Can C4 Therapeutics Inc. weather a recessionWeekly Stock Report & Stepwise Swing Trade Plans - خودرو بانک
Take Profit: Will C4 Therapeutics Inc. benefit from seasonality2025 Market WrapUp & AI Based Buy/Sell Signal Reports - khodrobank.com
Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
69,300 Shares: Travere Therapeutics Announces Major Employee Stock Grants with 4-Year Vesting Terms - Stock Titan
192,424 Shares in C4 Therapeutics, Inc. $CCCC Bought by Nuveen LLC - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 - BioSpace
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - Investing News Network
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Market reaction to C4 Therapeutics Inc.’s recent newsMarket Performance Summary & Accurate Trade Setup Notifications - Newser
C4 Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Sentiment & Weekly High Return Stock Opportunities - beatles.ru
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $8.00 Consensus Target Price from Brokerages - MarketBeat
C4 Therapeutics Inc. Breakout Confirmed by Volume MetricsQuarterly Profit Review & Community Verified Trade Signals - beatles.ru
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser
Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru
Market Pulse: Will C4 Therapeutics Inc. benefit from seasonality2025 Momentum Check & Real-Time Stock Price Movement Reports - خودرو بانک
Earnings Miss: What is C4 Therapeutics Inc.’s book value per shareJuly 2025 News Drivers & Technical Buy Zone Confirmation - خودرو بانک
What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک
Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):